Scarica l'app Stockscreener
19.22
4.63%
0.85
Dopo l'orario di chiusura:
19.22
Precedente Chiudi:
$18.37
Aprire:
$18.89
Volume 24 ore:
621.79K
Relative Volume:
0.67
Capitalizzazione di mercato:
$2.27B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-8.9395
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
-5.04%
1M Prestazione:
+27.12%
6M Prestazione:
-22.37%
1 anno Prestazione:
-10.31%
Intervallo 1D:
$18.50
$19.40
Intervallo di 1 settimana:
$17.49
$20.91
Portata 52W:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
19.22 | 2.27B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - Nasdaq
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - Stock Titan
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Invesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co. - Defense World
A closer look at NewAmsterdam Pharma Company NV (NAMS)’s stock price trends - uspostnews.com
Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
(NAMSW) Trading Report - news.stocktradersdaily.com
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Head to Head Survey: NewAmsterdam Pharma (NASDAQ:NAMS) vs. Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Is NewAmsterdam Pharma Company NV (NASDAQ: NAMS) A Good Investment Now? - Stocksregister
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares By Investing.com - Investing.com Canada
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - The Manila Times
NewAmsterdam Pharma adds Adele Gulfo to its Board By Investing.com - Investing.com South Africa
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares - Investing.com Australia
NewAmsterdam Pharma adds Adele Gulfo to its Board - Investing.com
Blockbuster Drug Veteran Who Led $12B Pfizer Unit Joins NewAmsterdam Board Before Critical Launch - Stock Titan
Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
KLP Kapitalforvaltning AS Purchases Shares of 6,000 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low – Here’s Why - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Average Price Target from Analysts - Defense World
Where are the Opportunities in (NAMSW) - news.stocktradersdaily.com
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):